首页> 外文期刊>Urology >Cystoscopic injections of dextranomer hyaluronic acid into proximal urethra for urethral incompetence: efficacy and adverse outcomes.
【24h】

Cystoscopic injections of dextranomer hyaluronic acid into proximal urethra for urethral incompetence: efficacy and adverse outcomes.

机译:尿道功能不全的膀胱镜下注射右旋糖酐透明质酸到尿道近端:疗效和不良后果。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To determine whether dextranomer/hyaluronic acid would be more efficacious or would produce fewer complications when using the material in a standard proximal-urethra cystoscopically-directed injection technique. Injectable periurethral bulking agents are an alternative to stress incontinence surgery. Dextranomer, a highly hydrophilic dextran polymer, solubilized in a base of nonanimal stabilized hyaluronic acid, has been approved as an injectable agent for the treatment of childhood vesicoureteric reflux (Deflux, Q-Med AB, Uppsala, Sweden), and in Europe for women with stress urinary incontinence (SUI) (Zuidex, Q-Med AB, Uppsala, Sweden). A previous multicenter trial demonstrated nonequivalence compared with bovine glutaraldehyde cross-linked collagen with a high complication rate. We sought to determine whether the failure of the treatment lay in the material itself or the use of a blind, midurethral injection technique. METHODS: A retrospective case series of 56 patients undergoing cystoscopically guided bladder neck injections of dextranomer/hyaluronic acid with follow-up in 42, included 35 women with intrinsic sphincter deficiency (ISD), 4 men with postprostatectomy incontinence, 2 men with sphincteric denervation secondary to spinal cord injury, and 1 woman with sphincteric failure after a neobladder. Outcome assessment used gender-appropriate International Consultation on Incontinence Questionnaire, clinical records, and/or urodynamic assessment. RESULTS: Of 35 women with ISD, 4 developed pseudoabscess formation with outlet obstruction requiring multiple operative interventions. Patient-defined treatment failure occurred in all 4 carefully selected postprostatectomy incontinent men, and in 23 of 35 females with ISD. CONCLUSIONS: Complications with cystoscopically injected dextranomer hyaluronic acid at the bladder neck occurred at a high rate, and using a validated questionnaire, the efficacy of dextranomer hyaluronic acid applied in this manner for ISD was poor.
机译:目的:确定在标准近端尿道膀胱镜定向注射技术中使用该材料时,右旋糖酐/透明质酸是更有效还是并发症更少。可注射的尿道周围填充剂是压力性尿失禁手术的替代方法。右旋糖酐是一种高度亲水性的右旋糖酐聚合物,可溶于非动物稳定的透明质酸中,已被批准用作治疗儿童膀胱输尿管反流的注射剂(Deflux,Q-Med AB,瑞典乌普萨拉),在欧洲,女性患有压力性尿失禁(SUI)(Zuidex,Q-Med AB,瑞典乌普萨拉)。先前的一项多中心试验表明,与牛戊二醛交联的胶原蛋白相比,并发症的发生率高。我们试图确定治疗失败的原因在于材料本身还是使用盲式,尿道中段注射技术。方法:回顾性分析了56例患者,其中42例患者接受了膀胱镜引导的右旋糖酐/透明质酸膀胱颈注射,并随访42例,其中包括35例固有括约肌缺乏症(ISD),4例前列腺切除术后失禁,2例继发括约肌神经失调的男性。脊髓损伤,一名新膀胱括约肌功能衰竭的妇女。结果评估使用适合性别的失禁问卷国际咨询,临床记录和/或尿动力学评估。结果:在35名ISD妇女中,有4名发展为假脓肿,出口阻塞,需要多种手术干预。患者定义的治疗失败发生在所有4名经过精心选择的前列腺切除术后失禁男性中,在35名患有ISD的女性中有23名。结论:膀胱镜注射右旋糖酐透明质酸在膀胱颈的并发症发生率很高,并且使用经过验证的问卷,以这种方式使用右旋糖酐透明质酸治疗ISD的疗效较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号